Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin and vasculogenic capacity of endothelial progenitor cells in type 2 diabetes
ChiCTR2100047733Phase 4Completed
- Sponsor
- The First Affiliated Hospital of Sun Yat-sen University
- Start
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of dapagliflozin in type 2 diabetes mellitus (T2DM), sponsored by The First Affiliated Hospital of Sun Yat-sen University. Primary endpoint: Fasting blood glucose. Started Jan 2020; status: completed.
02
Drugs
dapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR2100047733.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100047733.